ORION CORPORATION         STOCK EXCHANGE RELEASE        20 MARCH 2018 at 17.30 P.M. EET             
         

Orion Corporation: Organising meeting of the Board of Directors

The compositions of the Board committees were decided to be as follows:

Remuneration Committee:
Heikki Westerlund, Chairman
Timo Maasilta
Mikael Silvennoinen
 
Audit Committee:
Mikael Silvennoinen, Chairman
Ari Lehtoranta
Hilpi Rautelin
Eija Ronkainen
 
R&D Committee:
Sirpa Jalkanen, Chairman
Ari Lehtoranta
Timo Maasilta
Hilpi Rautelin
Eija Ronkainen
Mikael Silvennoinen
Heikki Westerlund
 
 
The members to the Nomination Committee were elected on 26 October 2017 as stated in the stock exchange release on the same day.
 
The Board of Directors has assessed the independence of its members and concluded that all the members are independent of the company and its significant shareholders.
 
 
 
Orion Corporation
 
 
 

Timo Lappalainen President and CEO

Olli Huotari SVP, Corporate Functions

 
 
 
                                                                                                                                   
Contact person:
Olli Huotari, SVP, Corporate Functions, Secretary of the Board of Directors, phone +358 50 966 3054
 
 
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
 
 
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,085 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki.